Search results
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 1 month agoThe consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical...
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend...
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
Investor's Business Daily· 6 months agoCelldex Therapeutics could rival a key Regeneron Pharmaceuticals drug, an analyst said Monday as...
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with...
Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely...
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the...
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Investor's Business Daily· 2 years agoCelldex Therapeutics took aim at Roche and Novartis' blockbuster hives treatment on Friday with a...
Celldex Therapeutics' (NASDAQ:CLDX) investors will be pleased with their enviable 762% return over...
Simply Wall St. via Yahoo Finance· 2 years agoCelldex Therapeutics, Inc. (NASDAQ:CLDX) shareholders have seen the share price descend 16% over the...
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate,...
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow...